ACE2 overexpression in corticotropin-releasing-hormone cells offers protection against pulmonary hypertension.
brain-lung axis
chronic hypoxia
dysautonomia
neuroimmune interaction
neuroinflammation
pulmonary hypertension
Journal
Frontiers in neuroscience
ISSN: 1662-4548
Titre abrégé: Front Neurosci
Pays: Switzerland
ID NLM: 101478481
Informations de publication
Date de publication:
2023
2023
Historique:
received:
16
05
2023
accepted:
21
07
2023
medline:
28
8
2023
pubmed:
28
8
2023
entrez:
28
8
2023
Statut:
epublish
Résumé
Pulmonary hypertension (PH), characterized by elevated pulmonary pressure and right heart failure, is a systemic disease involving inappropriate sympathetic activation and an impaired gut-brain-lung axis. Global overexpression of angiotensin converting enzyme 2 (ACE2), a cardiopulmonary protective enzyme of the renin-angiotensin system, attenuates PH induced by chronic hypoxia. Neurons within the paraventricular nucleus of the hypothalamus (PVN) that synthesize corticotropin-releasing hormone (CRH) are activated by stressors, like hypoxia, and this activation augments sympathetic outflow to cardiovascular tissues. These data coupled with our observations that ACE2 overexpression in CRH cells (CRH-ACE2KI mice) decreases anxiety-like behavior via suppression of hypothalamic-pituitary-adrenal (HPA) axis activity by decreasing CRH synthesis, led us to hypothesize that selective ACE2 overexpression in CRH neurons would protect against hypoxia-induced PH. CRH-ACE2KI and WT male and female mice were exposed to chronic hypoxia (10%O2) or normoxia (21%O2) for 4 weeks in a ventilated chamber with continuous monitoring of oxygen and carbon dioxide concentrations ( Chronic hypoxia induced a significant increase (36.4%) in right ventricular (RV) systolic pressure (RVSP) in WT mice, which was not observed in CRH-ACE2KI mice. No significant differences in RVSP were observed between male and female mice in any of the groups. Overexpression of ACE2 in CRH cells was protective against hypoxia-induced PH. Since the majority of expression of CRH is in brain nuclei such as paraventricular nucleus of the hypothalamus (PVN) and/or central nucleus of the amygdala (CeA) these data indicate that the protective effects of ACE2 are, at least in part, centrally mediated. This contributes to the systemic nature of PH disease and that CRH neurons may play an important role in PH.
Sections du résumé
Background
UNASSIGNED
Pulmonary hypertension (PH), characterized by elevated pulmonary pressure and right heart failure, is a systemic disease involving inappropriate sympathetic activation and an impaired gut-brain-lung axis. Global overexpression of angiotensin converting enzyme 2 (ACE2), a cardiopulmonary protective enzyme of the renin-angiotensin system, attenuates PH induced by chronic hypoxia. Neurons within the paraventricular nucleus of the hypothalamus (PVN) that synthesize corticotropin-releasing hormone (CRH) are activated by stressors, like hypoxia, and this activation augments sympathetic outflow to cardiovascular tissues. These data coupled with our observations that ACE2 overexpression in CRH cells (CRH-ACE2KI mice) decreases anxiety-like behavior via suppression of hypothalamic-pituitary-adrenal (HPA) axis activity by decreasing CRH synthesis, led us to hypothesize that selective ACE2 overexpression in CRH neurons would protect against hypoxia-induced PH.
Methods
UNASSIGNED
CRH-ACE2KI and WT male and female mice were exposed to chronic hypoxia (10%O2) or normoxia (21%O2) for 4 weeks in a ventilated chamber with continuous monitoring of oxygen and carbon dioxide concentrations (
Results
UNASSIGNED
Chronic hypoxia induced a significant increase (36.4%) in right ventricular (RV) systolic pressure (RVSP) in WT mice, which was not observed in CRH-ACE2KI mice. No significant differences in RVSP were observed between male and female mice in any of the groups.
Conclusion
UNASSIGNED
Overexpression of ACE2 in CRH cells was protective against hypoxia-induced PH. Since the majority of expression of CRH is in brain nuclei such as paraventricular nucleus of the hypothalamus (PVN) and/or central nucleus of the amygdala (CeA) these data indicate that the protective effects of ACE2 are, at least in part, centrally mediated. This contributes to the systemic nature of PH disease and that CRH neurons may play an important role in PH.
Identifiants
pubmed: 37638323
doi: 10.3389/fnins.2023.1223733
pmc: PMC10447887
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1223733Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL142776
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL142887
Pays : United States
Informations de copyright
Copyright © 2023 Oliveira, Karas, Alves, He, de Kloet, Krause, Richards, Bryant and Raizada.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Br J Pharmacol. 2021 Jan;178(1):187-202
pubmed: 31793661
Am J Pathol. 2005 Nov;167(5):1267-77
pubmed: 16251411
Physiol Rev. 2018 Jan 1;98(1):505-553
pubmed: 29351514
Emerg Med Int. 2018 Oct 11;2018:1758643
pubmed: 30405915
J Neurosci. 2021 May 26;41(21):4641-4657
pubmed: 33858944
Am J Respir Cell Mol Biol. 2018 Aug;59(2):271-273
pubmed: 30067089
Cardiol Clin. 2016 Aug;34(3):413-33
pubmed: 27443138
Am J Physiol Regul Integr Comp Physiol. 2018 Dec 1;315(6):R1167-R1182
pubmed: 30230933
Am J Respir Crit Care Med. 2018 Aug 15;198(4):422-423
pubmed: 29634285
Respir Res. 2017 Dec 4;18(1):201
pubmed: 29202826
Hypertension. 2009 Aug;54(2):365-71
pubmed: 19564552
J Renin Angiotensin Aldosterone Syst. 2015 Jun;16(2):249-53
pubmed: 25795458
Am J Physiol Lung Cell Mol Physiol. 2015 Feb 1;308(3):L229-52
pubmed: 25416383
Am J Respir Crit Care Med. 2012 Oct 15;186(8):780-9
pubmed: 22859525
Circ J. 2009 Dec;73(12):2337-41
pubmed: 19822980
Front Cell Neurosci. 2015 Aug 04;9:294
pubmed: 26300730
Neuropharmacology. 2018 May 1;133:85-93
pubmed: 29360543
Am J Respir Crit Care Med. 2010 Jun 1;181(11):1269-75
pubmed: 20194810
Am J Respir Crit Care Med. 2009 Jun 1;179(11):1048-54
pubmed: 19246717
Circulation. 2004 Sep 7;110(10):1308-12
pubmed: 15337703
Chest. 2006 Mar;129(3):746-52
pubmed: 16537877
Eur J Neurosci. 2013 Aug;38(4):2504-15
pubmed: 23651135
Am J Physiol Regul Integr Comp Physiol. 2013 Nov 15;305(10):R1112-23
pubmed: 24049118
Cell Rep. 2022 Mar 29;38(13):110600
pubmed: 35354026
AsiaIntervention. 2022 Mar;8(1):58-68
pubmed: 35350791
Respir Physiol Neurobiol. 2018 Oct;256:128-142
pubmed: 29174411
Eur Respir J. 2009 Oct;34(4):895-901
pubmed: 19443531
Pulm Circ. 2015 Jun;5(2):370-5
pubmed: 26064464
Exp Physiol. 2011 Mar;96(3):287-94
pubmed: 21148624
Am J Respir Crit Care Med. 2010 Oct 15;182(8):1065-72
pubmed: 20581171
JACC Cardiovasc Interv. 2022 Dec 12;15(23):2424-2426
pubmed: 36480985
N Engl J Med. 1991 Aug 29;325(9):618-24
pubmed: 1861695
JACC Cardiovasc Interv. 2022 Dec 12;15(23):2412-2423
pubmed: 36121246
Circulation. 1993 May;87(5 Suppl):IV90-6
pubmed: 8097970
Hypertension. 2020 Jul;76(1):206-216
pubmed: 32418496
Trends Cardiovasc Med. 2021 May;31(4):252-260
pubmed: 32413394
Pulm Circ. 2022 Jan 10;12(1):e12015
pubmed: 35506083
Am J Physiol Regul Integr Comp Physiol. 2019 Dec 1;317(6):R818-R833
pubmed: 31509428
J Med Econ. 2012;15(5):829-35
pubmed: 22455577
Nature. 2020 May;581(7807):204-208
pubmed: 32405000
Immunity. 2022 Aug 9;55(8):1466-1482.e9
pubmed: 35863346